NCT01230138已完成2 期
A Randomised, Double Blind, Placebo Controlled Efficacy and Safety Trial of Different Doses/Dose Regimens of FP187 Compared to Placebo in Moderate to Severe Plaque Psoriasis (Pivotal Registration Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 252
- 试验地点
- 2
- 主要终点
- Proportion of patients achieving PASI 75 compared to placebo
研究概览
简要总结
The purpose of this trial is to investigate the efficacy and safety of different doses and dose administrations of FP187 compared to a placebo treatment in patients with moderate to severe plaque psoriasis.
详细描述
The trial tests two different dose levels and two different daily dosing schedules (twice daily (BID) and three times daily (TID))over 20 weeks of treatment. Key is effect as measured by achievement of a 75% reduction in PASI after 20 weeks and safety monitored by adverse events and safety lab.
There are 3 active arms:
- FP-187 at a daily dose of 750mg divided in three doses (250mg TID)
- FP-187 at a daily dose of 750mg divided in two doses (375mg BID)
- FP-187 at a daily dose of 500mg divided in two doses (250mg BID)
and 1 placebo arm.
An additional open (flexible dosing) treatment arm has been amended to the trial
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients of either sex at least 18 years of age
- •A clinical diagnosis of plaque psoriasis defined as skin areas with erythema, induration and scaling, with a body surface area of no less than 10% and in total to be scoring at least 10 on the PASI scale
- •The psoriasis disease have been stable for at least 6 months at randomization
- •Signed and dated informed consent
- •Sexually active females of childbearing potential must be either surgically sterile (hysterectomy or tubal ligation) or use a highly effective (failure rate < 1%) medically accepted contraceptive method during the trial as well as one month after trial is finished such as:
- •Systemic contraceptive (oral, implant, injection),
- •Intrauterine device (IUD) inserted for at least one month prior to study entrance
- •Willingness and ability to comply with the trial procedures
- •Patient is beside the psoriasis disease in good general health in the opinion of the Investigator, as determined by medical history, physical examination, vital signs and clinical laboratory parameters (hematology, biochemistry and urinalysis).
排除标准
- •Female patients who are pregnant or breast-feeding or planning to become pregnant up to 7 months from treatment start as well as male patients plan-ning pregnancy with their partner up to 7 months from treatment start or practise unprotected sexual relationship up to 7 months from treatment start
- •Known allergy to any of the constituents of the product being tested
- •Pustular forms of psoriasis, erythrodermic or guttate psoriasis
- •Known immunosuppressive diseases (e.g., AIDS/HIV)
- •Presence of another serious or progressive disease which, according to the Investigator may interfere with treatment outcome
- •Active skin disease such as atopic dermatitis, rosacea, lupus erythematosus, or other inflammatory or infectious skin disease which, according to the Investigator may interfere with treatment outcome
- •Use of topical medical treatment or UVB treatment - Use of systemic anti-psoriatic treatment preceding the baseline visit Methotrexate, cyclosporine, steroids or PUVA treatment within x weeks; Biological treatment (efalizumab, adalimumab, infliximab, etanercept) within xx weeks; Acitretin within x months; Treatment with Fumaderm® or other DMF containing products during past xx weeks prior to baseline visit; Discontinuation of previous treatment with Fumaderm® or other DMF containing products due to lack of efficacy or side effects;
- •Has within the past x weeks prior to baseline visit been treated with drugs influencing the course of the psoriasis such as antimalarial drugs, beta-blockers or lithium
- •Has a relevant clinical history of stomach or intestinal problems (eg gastritis or peptic ulcer within the last 10 years )
- •Has liver enzyme measures (AST, ALT, Gamma-GT) higher than 2x UNL)
- •Has an estimated Creatinine Clearance: < xx ml/min
- •Has leucopenia (leukocyte count < x/mm3) or eosinophilia (count >x/µl) or lymphopenia (count < x/nl).
- •Has protein in the urine test at screening or baseline visit
- •Participation in another clinical trial during the last month preceding the baseline visit or participation in a trial with treatment of biologicals within x months prior to baseline visit
- •Patients who are involved in the organisation of the clinical investigation or are in any way dependant on the investigator or sponsor
研究组 & 干预措施
FP187 - TID
Experimental
FP187 250mg TID (total daily dose of 750mg)
干预措施: FP187 (Drug)
FP187- BID
Experimental
FP187 375mg BID (total daily dose of 750mg)of 750mg administered as 375mg BID
干预措施: FP187 (Drug)
FP187-LD-BID
Experimental
FP187 250mg BID (total daily dose of 500mg)
干预措施: FP187 (Drug)
Placebo
Placebo Comparator
Placebo treatment
干预措施: Placebo (Drug)
Open, flexible dosing treatment arm
Experimental
Open treatment using a flexible dosing schedule for 8 weeks with maximum dose of 750mg FP187 and with a total dosing of 20 weeks. All investigations following same schedule.
干预措施: FP187 (Drug)
结局指标
主要结局
Proportion of patients achieving PASI 75 compared to placebo
时间窗: After 20 weeks of treatment
Proportion of patients achieving PASI75 (a reduction in the PASI score of 75% or more)
次要结局
- PASI 75(At week 4, 8, 12 and 16)
- PASI 50(At week 4, 8, 12, 16 and 20)
- PASI 90(At week 4, 8, 12, 16 and 20)
- PGA (Physicians Global Assessment)(At week 4, 8, 12, 16 and 20)
- PaGA (Patients Global Assessment(At week 4,8,12,16 and 20)
- Pruritus(At week 4, 8, 12, 16 and 20)
- Patient rated QoL (Quality of Life)(At week 4, 8, 12, 16 and 20)
- Adverse events (AEs)(At week 4, 8, 12, 16 and 20)
- Safety lab test(At week 20)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.Schizoaffective DisorderPsychotic DisorderNCT00412373Johnson & Johnson Pharmaceutical Research & Development, L.L.C.307
已完成
2 期
Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With DiarrheaIrritable Bowel SyndromeNCT01130272Furiex Pharmaceuticals, Inc807
已完成
3 期
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)Irritable Bowel SyndromeNCT01553747Furiex Pharmaceuticals, Inc1,146
已完成
3 期
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)Irritable Bowel SyndromeNCT01553591Furiex Pharmaceuticals, Inc1,282
已完成
1 期
Evaluation of the Safety and Potential Therapeutic Effects of Cordstem-ST in Patients With Cerebral InfarctionCerebral InfarctionNCT02378974CHABiotech CO., Ltd18